Synchron said the financing would support commercialization of its first-generation Stentrode endovascular BCI, development of a higher-channel next-generation interface, and expansion of AI and engineering operations in New York and San Diego. The company also plans to accelerate pivotal trials and launch preparation. At the time of the announcement, 10 people with paralysis had received Stentrode implants in U.S. and Australian clinical trials.
Stentrode is delivered through the jugular vein and positioned in a blood vessel near the motor cortex, avoiding open-brain placement of an intracortical array. The financing shows that investors are prepared to fund the endovascular route through a more expensive clinical and manufacturing phase, although approval will depend on pivotal evidence and regulatory review.